Prosecution Insights
Last updated: April 18, 2026
Application No. 17/634,426

SYSTEMS AND METHOD FOR SMART PHACO IN SURGICAL SYSTEMS

Final Rejection §102§103
Filed
Feb 10, 2022
Examiner
GEIGER, RACHAEL L
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Johnson & Johnson Surgical Vision Inc.
OA Round
6 (Final)
85%
Grant Probability
Favorable
7-8
OA Rounds
2y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
93 granted / 109 resolved
+15.3% vs TC avg
Moderate +14% lift
Without
With
+14.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
28 currently pending
Career history
137
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
45.6%
+5.6% vs TC avg
§102
34.1%
-5.9% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102 §103
DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 24, 2025 has been entered. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections The objection of claim 20 is withdrawn based on the Applicant’s amendment. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-8, 10-13, 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Boukhny et al. (US 2011/0015563 A1—previously cited). Regarding claim 1, Boukhny discloses a smart auto phaco phacoemulsification system (paras. [0045]-[0110]), comprising: a surgical console 114 (para. [0046]) having at least one computing processor 116 capable of accessing at least one computing memory (para. [0049]-[0052]) associated with the at least one computing processor (para. [0049]-[0052]), wherein the surgical console is configured to receive one or more configuration variables (para. [0049]-[0052] ); and a surgical instrument 112 comprising a surgical tip 113, wherein the processor is configured to: track time duration during which a maximum targeted ultrasound power is applied during a phacoemulsification surgical procedure, initiate a reset of ultrasound power in response to the time duration reaching a threshold value, and cause the surgical instrument to release or dispense the at least one or more particles from the at least one surgical tip in accordance with the one or more configuration variables (i.e., para. [0069] discloses the temperature of the eye (i.e., threshold value) is determined by performing calculations at specific time intervals, para. [0070] discloses that the amount of power is reduced based on decreasing the duty cycle of the ultrasound signal if the estimated temperature exceeds the threshold value; see also (para. [0076]-[0084] such that power may be pulsed or reset, therefore, the amount of time that the power is “on” is tracked and can be pulsed or shut “off” for a period of time depending on the temperature reaching or exceeding a threshold value, as such the surgical instrument would release the particles of tissue from the distal end that were being treated during the burst (see paras. [0084]-[0086]) and additionally discloses aspiration vacuum and irrigation pressure (paras. [0050]-[0060]); note: see also paras. [0088]-[0089] which discloses not only duration of both cutting intervals and sense intervals, but also that during the interval a maximum amount of power (i.e., all of the power by the surgeon’s request as disclosed by para. [0089]), and the next cutting interval have no power)). Regarding claim 2, Boukhny discloses the system of claim 1. Boukhny also discloses wherein the one or more configuration variables include one or more of: auto phaco on/off (para. [0077]), max power (para. [0077]), max VAC (para. [0050]), threshold (para. [0068]), and total active time (para. [0069], [0073], [0077]-[0080]). Regarding claim 3, Boukhny discloses the system of claim 2. Boukhny also discloses the one or more configuration variables are entered into the system by a user (para. [0072]). Regarding claim 4, Boukhny discloses the system of claim 2. Boukhny also discloses the one or more configuration variables are based on historical data gathered over time with respect to a specific surgeon (para. [0051]). Regarding claim 5, Boukhny discloses the system of claim 2. Boukhny also discloses the one or more configuration variables are based at least in part on user-entered variables and historical (para. [0049]-[0051]). Regarding claim 6, Boukhny discloses the system of claim 2. Boukhny also discloses additional variables are determined in response to the one or more configuration variables being related, sharing same functionalities, or depending on each other (para. [0049]-[0052]). Regarding claim 7, Boukhny discloses the system of claim 6. Boukhny also discloses the additional variables are extracted and calculated from the inputted one or more configuration variables (i.e., see para. [0049]-[0052], [0073]-[0077]). Regarding claim 8, Boukhny discloses the system of claim 6. Boukhny also discloses the at least one computer processor is configured to cause an ultrasound power reset based at least in part on an ultrasound power condition meeting at least one of the additional variables (paras. [0072]-[0080]). Regarding claim 10, Scheller discloses an auto phaco system (paras. [0045]-[0110]) including a surgical console 114 (para. [0046]) and a surgical instrument 112, the system having at least one processor 116 coupled to a memory (para. [0049]), the processor being configured to: receive one or more data inputs as initial data settings (variables; para. [0049]-[0052]); extract one or more further data inputs from the received one or more data inputs (paras. [0061], [0068]-[0070]), track time duration during which a maximum targeted ultrasound power is applied during a phacoemulsification surgical procedure, initiate a reset of ultrasound power in response to the time duration reaching a threshold value, and cause the surgical instrument to release or dispense the at least one or more particles from the at least one surgical tip in accordance with the one or more configuration variables (i.e., para. [0069] discloses the temperature of the eye (i.e., threshold value) is determined by performing calculations at specific time intervals, para. [0070] discloses that the amount of power is reduced based on decreasing the duty cycle of the ultrasound signal if the estimated temperature exceeds the threshold value; see also (para. [0076]-[0084] such that power may be pulsed or reset, therefore, the amount of time that the power is “on” is tracked and can be pulsed or shut “off” for a period of time depending on the temperature reaching or exceeding a threshold value, as such the surgical instrument would release the particles of tissue from the distal end that were being treated during the burst (see paras. [0084]-[0086]) and additionally discloses aspiration vacuum and irrigation pressure (paras. [0050]-[0060])). Regarding claim 11, Boukhny discloses the system of claim 10. Boukhny also discloses the received one or more data inputs are received from a user interface (para. [0072]). Regarding claim 12, Boukhny discloses the system of claim 10. Boukhny also discloses the received one or more data inputs are based on historical data (para. [0051]). Regarding claim 13, Boukhny discloses the system of claim 10. Boukhny also discloses the received one or more data inputs are received from a user interface and based on historical data (para. [0049]-[0051]). Regarding claim 20, Boukhny discloses the system of claim 1. Boukhny further discloses a fluid line 130, 132, 134 operatively coupled to the surgical instrument (para. [0049]); and a sensor 122 operatively coupled to the fluid line (para. [0049]), wherein the sensor is configured measure a pressure in the fluid line (para. [0049]), wherein the at least one computing processor is configured to detect an occlusion at the at least one surgical tip based on a pressure measurement (para. [0050]-[0053]), and wherein the at least one computer processor is further configured to cause an ultrasound power reset and to active the venting system based on detection of the occlusion for a period of time (para. [0067]-[0080]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Boukhny in view of Kuebler (US 2011/0092896 A1—previously cited). Regarding claim 9, Boukhny discloses the system of claim 6. Boukhny doesn’t directly disclose discloses the system is configured to automatically release or discharge the one or more particles from the at least one surgical tip based on ultrasound power reaching a value of at least one of the additional variables. In the same field of endevaor, namely surgical systems, Kuebler discloses (paras. [0022]-[0032] a similar device including a handpiece 4 of a phaco-emulsification system that includes vibrating tip 5, an irrigation line 3, an irrigation valve 40, and a venting valve 17. Kuebler also discloses the venting system is configured to automatically release or discharge the one or more particles from the at least one surgical tip based on ultrasound power reaching a value of at least one of the additional variables (para. [0029]-[0031]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Boukhny to automatically release or discharge the one or more particles from the at least one surgical tip based on ultrasound power reaching a value of at least one of the additional variables for purposes of forcing the particle causing an occlusion away from the needle tip such that the occlusion is no longer present in the system (para. [0029]). Claim 16 is rejected under 35 U.S.C. 103 as being unpatentable over Boukhny. Regarding claim 16, Boukhny discloses the system of claim 10. Boukhny doesn’t expressly disclose the threshold value is 3 seconds as required by the claim. Instead, Boukhny discloses recording over a period of time, temperature calculations (para. [0069]), and that the temperature needs to be optimized such that it doesn’t reach a temperature threshold to cause tissue damage. As such, the device has “on” and “off” times to reduce the temperature of the tip. Therefore, the time that the power is on (and off) is disclosed to be a result effective variable in that changing the time would change the temperature of the tip during the treatment (para. [0080]). Additionally, the Applicant’s disclosure does not teach any criticality or importance to the value being 3 seconds (para. [0037]). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Boukhny by having the time to 3 seconds (i.e., to keep the device cool) as a matter of routine optimization since a person of ordinary skill in the art would have a reasonable expectation of success and since it has been held that “where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Response to Arguments Applicant's arguments filed October 24, 2025 have been fully considered but they are not persuasive. Specifically, Applicant argues that Boukhny fails to disclose: Track time duration during which a maximum targeted ultrasound power is applied during a phacoemulsification surgical procedure and initiate a reset of ultrasound power in response to the time duration reaching a threshold value. Examiner disagrees. In addition to the explanation in claim 1, Examiner further clarifies and cites paras. [0088]-[0089] of Boukhny and specifically that these paragraphs disclose: Track time duration (i.e., the duration of the cutting interval and sense intervals as disclosed in para. [0088] which are approximately the same) during which a maximum targeted ultrasound power is applied during a phacoemulsification surgical procedure (i.e., approximately all of the power requested by the surgeon as disclosed by para. [0089]) and initiate a reset of ultrasound power (i.e., none of the power as disclosed in para. [0089]) in response to the time duration reaching a threshold value (i.e., during which the first cutting interval was completed at the maximum power and the subsequent cutting interval has no power). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHAEL LYNN GEIGER whose telephone number is (571)272-6196. The examiner can normally be reached Mon-Fri 8:00am-5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached on 5712724695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RACHAEL L GEIGER/ Examiner, Art Unit 3771 /BROOKE LABRANCHE/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Feb 10, 2022
Application Filed
May 29, 2024
Non-Final Rejection — §102, §103
Sep 04, 2024
Response Filed
Oct 15, 2024
Final Rejection — §102, §103
Jan 22, 2025
Request for Continued Examination
Jan 23, 2025
Response after Non-Final Action
Feb 06, 2025
Non-Final Rejection — §102, §103
May 12, 2025
Response Filed
Jun 17, 2025
Final Rejection — §102, §103
Sep 26, 2025
Response after Non-Final Action
Oct 24, 2025
Request for Continued Examination
Oct 27, 2025
Response after Non-Final Action
Dec 22, 2025
Non-Final Rejection — §102, §103
Mar 17, 2026
Response Filed
Apr 09, 2026
Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12588923
DEVICE FOR PERFORMING A COSMETIC OR MEDICAL PROCEDURE
2y 5m to grant Granted Mar 31, 2026
Patent 12569361
DEVICES AND METHODS TO TREAT AND PREVENT DIVERTICULITIS
2y 5m to grant Granted Mar 10, 2026
Patent 12564412
PERCUTANEOUS ACCESS PATHWAY SYSTEM
2y 5m to grant Granted Mar 03, 2026
Patent 12558103
REPAIR ASSEMBLY AND REPAIR ASSEMBLY IMPLANTATION DEVICE
2y 5m to grant Granted Feb 24, 2026
Patent 12539108
MEDICAL DEVICES AND RELATED METHODS
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
85%
Grant Probability
99%
With Interview (+14.1%)
2y 9m
Median Time to Grant
High
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month